OVARIAN CARCINOMA, RECURRENT
Clinical trials for OVARIAN CARCINOMA, RECURRENT explained in plain language.
Never miss a new study
Get alerted when new OVARIAN CARCINOMA, RECURRENT trials appear
Sign up with your email to follow new studies for OVARIAN CARCINOMA, RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immune cell therapy takes on recurrent ovarian cancer
Disease control Recruiting nowThis early-phase study tests a new treatment called CIML NK cell therapy for people with recurrent ovarian cancer that no longer responds to platinum-based chemotherapy. The therapy uses specially trained natural killer cells from a donor to attack the cancer. The study aims to f…
Matched conditions: OVARIAN CARCINOMA, RECURRENT
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 17, 2026 10:26 UTC
-
New hope for ovarian cancer patients resistant to current treatments
Disease control Recruiting nowThis study tests a drug called trastuzumab deruxtecan (T-DXd) in people with ovarian cancer that has come back after treatment with PARP inhibitors. The drug targets a protein called HER2 found on some cancer cells. About 116 adults with HER2-positive ovarian cancer will be rando…
Matched conditions: OVARIAN CARCINOMA, RECURRENT
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated May 15, 2026 11:55 UTC